These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 39034813)

  • 1. Prognosis of concurrent renal impairment at diagnosis of multiple myeloma: a systematic review.
    Zhang Y; Pan J; Kang H; Peng S; Tung TH; Shen B
    Ann Med; 2024 Dec; 56(1):2380301. PubMed ID: 39034813
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Renal impairment at presentation in multiple myeloma continues to be associated with poor survival.
    Laing AA; Geddes C; Soutar R
    Br J Haematol; 2015 Jun; 169(6):901-2. PubMed ID: 25522297
    [No Abstract]   [Full Text] [Related]  

  • 3. [Clinical and laboratory features and prognostic implications in myeloma with and without renal impairment].
    Griniūte R; Bumblyte IA
    Medicina (Kaunas); 2003; 39 Suppl 1():41-7. PubMed ID: 12761419
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The use of novel drugs can effectively improve response, delay relapse and enhance overall survival in multiple myeloma patients with renal impairment.
    Uttervall K; Duru AD; Lund J; Liwing J; Gahrton G; Holmberg E; Aschan J; Alici E; Nahi H
    PLoS One; 2014; 9(7):e101819. PubMed ID: 25003848
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Analysis of renal impairment in MM-003, a phase III study of pomalidomide + low - dose dexamethasone versus high - dose dexamethasone in refractory or relapsed and refractory multiple myeloma.
    Weisel KC; Dimopoulos MA; Moreau P; Lacy MQ; Song KW; Delforge M; Karlin L; Goldschmidt H; Banos A; Oriol A; Alegre A; Chen C; Cavo M; Garderet L; Ivanova V; Martinez-Lopez J; Knop S; Yu X; Hong K; Sternas L; Jacques C; Zaki MH; San Miguel J
    Haematologica; 2016 Jul; 101(7):872-8. PubMed ID: 27081177
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Renal Impairment at Diagnosis in Myeloma: Patient Characteristics, Treatment, and Impact on Outcomes. Results From the Australia and New Zealand Myeloma and Related Diseases Registry.
    Ho PJ; Moore EM; McQuilten ZK; Wellard C; Bergin K; Augustson B; Blacklock H; Harrison SJ; Horvath N; King T; Mollee P; Quach H; Reid C; Rosengarten B; Walker P; Wood EM; Spencer A
    Clin Lymphoma Myeloma Leuk; 2019 Aug; 19(8):e415-e424. PubMed ID: 31208889
    [TBL] [Abstract][Full Text] [Related]  

  • 7. First-line therapy with bendamustine/prednisone/bortezomib-A GMMG trial for non-transplant eligible symptomatic multiple myeloma patients.
    Knauf W; Dingeldein G; Schlag R; Welslau M; Moehler T; Terzer T; Walter S; Habermehl C; Kunz C; Goldschmidt H; Raab MS;
    Eur J Haematol; 2020 Aug; 105(2):116-125. PubMed ID: 32155662
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Renal impairment and use of nephrotoxic agents in patients with multiple myeloma in the clinical practice setting in the United States.
    Qian Y; Bhowmik D; Bond C; Wang S; Colman S; Hernandez RK; Cheng P; Intorcia M
    Cancer Med; 2017 Jul; 6(7):1523-1530. PubMed ID: 28612485
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bortezomib before and after autologous stem cell transplantation overcomes the negative prognostic impact of renal impairment in newly diagnosed multiple myeloma: a subgroup analysis from the HOVON-65/GMMG-HD4 trial.
    Scheid C; Sonneveld P; Schmidt-Wolf IG; van der Holt B; el Jarari L; Bertsch U; Salwender H; Zweegman S; Blau IW; Vellenga E; Weisel K; Pfreundschuh M; Jie KS; Neben K; van de Velde H; Duehrsen U; Schaafsma MR; Lindemann W; Kersten MJ; Peter N; Hänel M; Croockewit S; Martin H; Wittebol S; Bos GM; van Marwijk-Kooy M; Wijermans P; Goldschmidt H; Lokhorst HM
    Haematologica; 2014 Jan; 99(1):148-54. PubMed ID: 23996482
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Severe renal impairment as an adverse prognostic factor for survival in newly diagnosed multiple myeloma patients.
    Chen X; Luo X; Zu Y; Issa HA; Li L; Ye H; Yang T; Hu J; Wei L
    J Clin Lab Anal; 2020 Sep; 34(9):e23416. PubMed ID: 32710448
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bortezomib-based treatment for multiple myeloma patients with renal impairment: A systematic review and meta-analysis of observational studies.
    Zhu W; Chen W
    Medicine (Baltimore); 2016 Nov; 95(46):e5202. PubMed ID: 27861343
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of renal impairment on outcomes with lenalidomide and dexamethasone treatment in the FIRST trial, a randomized, open-label phase 3 trial in transplant-ineligible patients with multiple myeloma.
    Dimopoulos MA; Cheung MC; Roussel M; Liu T; Gamberi B; Kolb B; Derigs HG; Eom H; Belhadj K; Lenain P; Van der Jagt R; Rigaudeau S; Dib M; Hall R; Jardel H; Jaccard A; Tosikyan A; Karlin L; Bensinger W; Schots R; Leupin N; Chen G; Marek J; Ervin-Haynes A; Facon T
    Haematologica; 2016 Mar; 101(3):363-70. PubMed ID: 26659916
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Renal failure in multiple myeloma: Specific management issues].
    Try M; Harel S
    Bull Cancer; 2024; 111(7-8):733-740. PubMed ID: 36759215
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Multiple myeloma: from diagnosis to treatment.
    Eslick R; Talaulikar D
    Aust Fam Physician; 2013 Oct; 42(10):684-8. PubMed ID: 24130968
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Urinary proteins and renal dysfunction in patients with multiple myeloma.
    Corso A; Zappasodi P; Lazzarino M
    Biomed Pharmacother; 2002 May; 56(3):139-43. PubMed ID: 12046685
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Renal failure in multiple myeloma: reversibility and impact on the prognosis. Nordic Myeloma Study Group.
    Knudsen LM; Hjorth M; Hippe E
    Eur J Haematol; 2000 Sep; 65(3):175-81. PubMed ID: 11007053
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Report of 134 Newly Diagnosed Multiple Myeloma Patients with Renal Impairment.
    Liu A; Yang G; Geng C; Wang H; Li L; Li Y; Wu Y; Tian Y; Leng Y; Wang G; Gao W; Chen W
    Acta Haematol; 2016; 135(3):140-5. PubMed ID: 26587903
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Current treatments for renal failure due to multiple myeloma.
    Gavriatopoulou M; Terpos E; Kastritis E; Dimopoulos MA
    Expert Opin Pharmacother; 2016 Nov; 17(16):2165-2177. PubMed ID: 27646819
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Renal impairment in multiple myeloma and related disorders].
    Wakui H
    Rinsho Ketsueki; 2013 Oct; 54(10):1876-87. PubMed ID: 24064839
    [No Abstract]   [Full Text] [Related]  

  • 20. Factors affecting outcome of patients with multiple myeloma.
    Basit A; Siddiqui N; Hameed A; Muzaffar N; Athar S
    J Ayub Med Coll Abbottabad; 2014; 26(3):376-9. PubMed ID: 25671952
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.